HUP9902553A2 - Mikrocseppekből álló propofol készítmények - Google Patents

Mikrocseppekből álló propofol készítmények

Info

Publication number
HUP9902553A2
HUP9902553A2 HU9902553A HUP9902553A HUP9902553A2 HU P9902553 A2 HUP9902553 A2 HU P9902553A2 HU 9902553 A HU9902553 A HU 9902553A HU P9902553 A HUP9902553 A HU P9902553A HU P9902553 A2 HUP9902553 A2 HU P9902553A2
Authority
HU
Hungary
Prior art keywords
propofol
microdroplets
volume
phospholipid
fat
Prior art date
Application number
HU9902553A
Other languages
English (en)
Inventor
Duncan H. Haynes
Original Assignee
Research Triangle Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24469788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9902553(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Research Triangle Pharmaceuticals Ltd. filed Critical Research Triangle Pharmaceuticals Ltd.
Publication of HUP9902553A2 publication Critical patent/HUP9902553A2/hu
Publication of HUP9902553A3 publication Critical patent/HUP9902553A3/hu
Publication of HU225046B1 publication Critical patent/HU225046B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Motorcycle And Bicycle Frame (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A találmány tárgyát steril, injekciós felhasználásra alkalmas propofoltartalmú gyógyászati készítmény képezi, amely lényegébenmikrocseppeket tartalmaz, amely mérete mintegy 210-5 mm és 110-3 mmközötti, amely mikrocseppek ultrahangos kezeléssel, homogenizálással,mikrofluidizációval vagy egyéb nagy nyíróerőt biztosító művelettelkészülnek, és amely mikrocseppek összefolyás ellen stabilizáltpropofol magból állnak, amelyek foszfolipid membránréteggel vannakbevonva, ahol a propofol térfogatnak a foszfolipid membránrétegtömegéhez viszonyított aránya legalább 1,0 ml/g, és ahol a zsíroktólés trigliceridektől mentes készítmény legalább 3 tömeg/térfogat%propofolt tartalmaz, és gyógyászatilag megfelelő, injekciós célraalkalmas segéd- és vivőanyagot tartalmaz. Ezen foszfolipidréteggelbevont találmány szerinti mikrocseppek anesztetizálásra és nyugtatásraalkalmazhatók hosszabb időn keresztül anélkül, hogy a kezelt betegszervezetébe zsírt vinnénk be. A találmány szerinti gyógyászati készítmény bakteriosztatikus ésbaktericid hatást is mutat, így hosszú időn keresztül tárolható. Ó
HU9902553A 1996-03-19 1997-03-17 Mikrocseppekbõl álló propofolkészítmények HU225046B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/616,511 US5637625A (en) 1996-03-19 1996-03-19 Propofol microdroplet formulations
PCT/US1997/004168 WO1997034588A1 (en) 1996-03-19 1997-03-17 Propofol microdroplet formulations

Publications (3)

Publication Number Publication Date
HUP9902553A2 true HUP9902553A2 (hu) 2000-10-28
HUP9902553A3 HUP9902553A3 (en) 2001-04-28
HU225046B1 HU225046B1 (hu) 2006-05-29

Family

ID=24469788

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902553A HU225046B1 (hu) 1996-03-19 1997-03-17 Mikrocseppekbõl álló propofolkészítmények

Country Status (19)

Country Link
US (1) US5637625A (hu)
EP (1) EP0796616B1 (hu)
JP (1) JP2000507244A (hu)
KR (1) KR100484516B1 (hu)
CN (1) CN1124845C (hu)
AT (1) ATE182074T1 (hu)
AU (1) AU719756B2 (hu)
BR (1) BR9708099B8 (hu)
CA (1) CA2249375C (hu)
DE (1) DE69700317T2 (hu)
DK (1) DK0796616T3 (hu)
ES (1) ES2135969T3 (hu)
FI (1) FI982009A (hu)
GR (1) GR3031414T3 (hu)
HU (1) HU225046B1 (hu)
NO (1) NO324498B1 (hu)
NZ (1) NZ331669A (hu)
RU (1) RU2186564C2 (hu)
WO (1) WO1997034588A1 (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ATE386506T1 (de) * 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
CH692322A5 (it) * 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
CN100462066C (zh) * 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
PE20000264A1 (es) 1998-02-10 2000-04-11 Gensia Sicor Inc Composicion de propofol que contiene sulfito
WO1999040906A2 (en) * 1998-02-11 1999-08-19 Research Triangle Pharmaceuticals Method and composition for treatment of inflammatory conditions
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
ATE259220T1 (de) 1998-05-29 2004-02-15 Skyepharma Canada Inc Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
CN1221249C (zh) * 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
ID29270A (id) 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
PT1143962E (pt) * 1999-01-28 2005-03-31 Kurani Shashikant Prabhudas Solucao parenterica de propofol (2,6-di-isopropilfenol) e 2,5-di-o-metil-1,4;3,6-di-anidro-d-glucitol, como dissolvente
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
EP1214059B1 (en) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US6071933A (en) * 1999-12-03 2000-06-06 Diversified Medical Innovations, Inc. Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use
GB2359747B (en) 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
CA2407027C (en) 2000-04-20 2011-02-15 Rtp Pharma Inc. Improved water-insoluble drug particle process
JP2003535884A (ja) 2000-06-16 2003-12-02 スカイファーマ・カナダ・インコーポレーテッド プロポフォールの改善された注射可能な分散物
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
ATE357216T1 (de) * 2001-02-22 2007-04-15 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
WO2003000236A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
CA2461349C (en) * 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
WO2003026632A2 (en) 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
UA76802C2 (uk) * 2001-12-28 2006-09-15 Мгі Гп, Інк. Фармацевтичний препарат водорозчинних проліків пропофолу на водній основі (варіанти)
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003086413A1 (en) * 2002-04-08 2003-10-23 Guilford Pharmaceuticals, Inc. Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
RS54275B1 (sr) * 2002-07-29 2016-02-29 Transform Pharmaceuticals, Inc. Vodeni 2,6-diizopropilfenol farmaceutski sastavi
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
CN1708270A (zh) * 2002-10-29 2005-12-14 转化医药公司 丙泊酚与半胱氨酸
TW200420287A (en) * 2002-12-06 2004-10-16 Otsuka Pharma Co Ltd Propofol-containing fat emulsions
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US7182948B2 (en) * 2003-08-04 2007-02-27 Ko Manufacturing, Inc. Topical veterinary compositions and methods for the treatment and prevention of infection
EP1706148A2 (en) * 2004-01-14 2006-10-04 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
CN103054798B (zh) * 2005-08-31 2021-03-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
KR20080080119A (ko) * 2005-11-15 2008-09-02 백스터 인터내셔널 인코포레이티드 리폭시게나제 억제제의 조성물
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
RU2535001C1 (ru) * 2013-07-11 2014-12-10 Общество с ограниченной ответственностью "ВИК-здоровье животных" Микроколлоидный раствор пропофола для анестезии
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
CN107708670A (zh) * 2015-06-01 2018-02-16 奥托泰利克有限责任公司 磷脂包衣的治疗剂纳米颗粒和有关的方法
WO2017218630A2 (en) * 2016-06-15 2017-12-21 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
BR112022005497A2 (pt) * 2019-12-20 2022-06-21 Fresenius Kabi Austria Gmbh Método para produzir emulsões de óleo em água
EP4056038A1 (en) * 2021-03-10 2022-09-14 Basf Se Microparticles containing active substances

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
DE4132677C2 (de) * 1991-10-01 1995-08-24 Braun Melsungen Ag Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations

Also Published As

Publication number Publication date
JP2000507244A (ja) 2000-06-13
BR9708099B1 (pt) 2010-02-23
NO984370D0 (no) 1998-09-18
BR9708099B8 (pt) 2014-04-29
FI982009A0 (fi) 1998-09-17
NZ331669A (en) 2000-01-28
HU225046B1 (hu) 2006-05-29
BR9708099A (pt) 2000-01-04
AU2329297A (en) 1997-10-10
DE69700317T2 (de) 1999-12-02
KR20000064762A (ko) 2000-11-06
EP0796616B1 (en) 1999-07-14
EP0796616A1 (en) 1997-09-24
NO324498B1 (no) 2007-10-29
WO1997034588A1 (en) 1997-09-25
DE69700317D1 (de) 1999-08-19
CA2249375A1 (en) 1997-09-25
US5637625A (en) 1997-06-10
RU2186564C2 (ru) 2002-08-10
NO984370L (no) 1998-09-18
KR100484516B1 (ko) 2005-09-02
GR3031414T3 (en) 2000-01-31
HUP9902553A3 (en) 2001-04-28
AU719756B2 (en) 2000-05-18
CN1218398A (zh) 1999-06-02
CN1124845C (zh) 2003-10-22
ES2135969T3 (es) 1999-11-01
FI982009A (fi) 1998-09-17
CA2249375C (en) 2002-06-18
ATE182074T1 (de) 1999-07-15
DK0796616T3 (da) 1999-11-29

Similar Documents

Publication Publication Date Title
HUP9902553A2 (hu) Mikrocseppekből álló propofol készítmények
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
ATE496643T1 (de) Verwendung von antioxidantien zur verhinderung von oxidation und zur reduzierung von wirkstoffzersetzung in wirkstoffhaltigen medizinischen artikeln
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE252899T1 (de) Schilddrüsenhormone enthaltende mittel
BG103552A (en) Therapeutical forms
FI971951A0 (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
ATE283047T1 (de) Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose
ES2088959T3 (es) 11-beta-aril-4-estreno, procedimiento para su preparacion y aplicacion como medicamento.
GR861803B (en) Novel carbonic acid derivatives method for their preparation their use and medicine containing them
DE60112777D1 (de) Beschichtete medizinische geräte und verfahren zur sterilisation
MX9805705A (es) Compuestos biaromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
NO302016B1 (no) Anordning for tilförsel i et legeme av innkapslet biologisk materiale
CS9001136A2 (en) Method of transdermal therapeutical system's production with active substance's graded liberation and application for active substances' local or systemic administration
FR2713640B1 (fr) Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
ATE127020T1 (de) Pharmazeutische zusammensetzungen mit eierschalenbestandteilen und ihre herstellung und verwendung.
ATE184788T1 (de) Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
von KROGH Podophyllotoxin in serum: Absorption subsequent to three-day repeated applications of a 0.5% ethanolic preparation on condylomata acuminata

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees